{"id":{"repo_id":"msu","oai_identifier":"oai:d.lib.msu.edu:etd_53147"},"canonical_url":"https://search.ndltd.org/etd/msu/oai:d.lib.msu.edu:etd_53147","repository":{"repo_id":"msu","name":"Michigan State University","base_url":"https://d.lib.msu.edu/oai"},"display":{"title":"VASCULAR CHEMERIN AS A DRIVER OF OBESITY-RELATED HYPERTENSION AND VASCULAR STIFFNESS","abstract":"Thesis (Ph.D.)--Michigan State University. Pharmacology and Toxicology - Doctor of Philosophy, 2026","abstract_html":"Thesis (Ph.D.)--Michigan State University. Pharmacology and Toxicology - Doctor of Philosophy, 2026","abstract_has_math":false,"creators":["Wabel, Emma Ann"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Watts, Stephanie W","Alan, Jamie","Fink, Gregory D","Mullick, Adam"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-18T18:59:41Z","subjects":["Pharmacology","Physiology"],"languages":["eng"],"rights":["In Copyright"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:53147","local:Wabel_grad.msu_0128D_22164"],"render_values":[{"text":"etd:53147","href":null,"code":true},{"text":"local:Wabel_grad.msu_0128D_22164","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/doi:10.25335/tvsb-q426","outbound_label":"DOI","outbound_source":"dc:identifier","record_url":"https://doi.org/doi:10.25335/tvsb-q426","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://d.lib.msu.edu/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Ad.lib.msu.edu%3Aetd_53147","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Watts, Stephanie W","Alan, Jamie","Fink, Gregory D","Mullick, Adam"]},{"key":"dc:creator","label":"Author","values":["Wabel, Emma Ann"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2026"]},{"key":"dc:relation","label":"Dc Relation","values":["Electronic Theses & Dissertations"]},{"key":"dc:type","label":"Dc Type","values":["text","Electronic dissertations"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Pharmacology","Physiology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["In Copyright"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:53147","local:Wabel_grad.msu_0128D_22164","https://doi.org/doi:10.25335/tvsb-q426"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Thesis (Ph.D.)--Michigan State University. Pharmacology and Toxicology - Doctor of Philosophy, 2026","Chemerin is an adipokine steadily gaining attention as a factor in human disease. Circulating levels of chemerin are positively associated with a host of pathologies, including obesity, hypertension, and vascular stiffness. Chemerin causes direct vasoconstriction of isolated blood vessels through the Chemerin1 receptor. Loss of chemerin results in modest falls in blood pressure in standard diet-fed rats and major falls in blood pressure in rats made hypertensive by high fat diet (HFD) feeding. Though the liver makes the majority of chemerin in circulation, loss of chemerin in the liver alone does not significantly change blood pressure. Recognizing that chemerin drives adiposity-associated hypertension, but contributions of chemerin by the liver are not responsible for this, we in turn hypothesize that the chemerin made in the vasculature—the blood vessels and their surrounding perivascular adipose tissue (PVAT)—is important for blood pressure support and pathology. We first investigated chemerin production in and activity at the vasculature. We visualized chemerin (Rarres2) and Chemerin 1 receptor (CMKLR1) expression in each layer of the vasculature— the endothelium, media, adventitia, and PVAT. Then, using the Chemerin1 selective inhibitor CCX832, we demonstrated that chemerin supports basal (uncontracted) blood vessel tone. Next, we sought to identify potential mechanisms that chemerin alters vascular function. We found that inhibition of the receptor Chemerin1 via CCX832 blunted norepinephrine and serotonin-induced vasoconstriction in the male rat, indicating chemerin’s role in amplifying some forms of agonist-induced vasoconstriction. This finding was observed only in vessels with PVAT intact, indicating that it is likely chemerin from the PVAT that drives this effect. Further, chemerin’s amplification of contractile agents occurred only in vessels from male rats, not female rats, indicating a potential sex-dependent role of chemerin in vessel contractility. We then investigated chemerin’s role in adiposity-associated hypertension in whole animals. Administration of CCX832 reduced blood pressure in HFD-induced, but not HSD-induced hypertensive males, supporting that chemerin’s effects on blood pressure are adiposity-related and at least in part Chemerin1-mediated. KO of chemerin blunted HFD-induced hypertension in males and exacerbated it in females, revealing a sex difference previously undiscovered. Interestingly, male KO rats were also protected from HFD-induced aortic stiffening, a blood pressure-independent marker of cardiovascular disease. We consistently observe that chemerin plays a more significant role in HFD-induced diseased vs normal states. What continues to perplex us is how this protein has a greater effect in the body. We investigated whether chemerin processing—cleavage from inactive Chemerin-163 to active Chemerin-157—changed in tissues isolated from CD and HFD animals. However, due to rapid degradation of the chemerin protein, measures could not be achieved. Insight into chemerin’s instability in the body indicates that chemerin is produced, released, and activated locally to exert its effects. Together, these data identify the vasculature as an important site of chemerin synthesis and activity, highlight a previously-missed sex difference for chemerin in vessel contractility and blood pressure, and propose a mechanism by which chemerin’s control in cardiovascular health and diseases hinges. Through this body of work, we assert the adipokine chemerin as a sex-specific therapeutic target in cardiovascular disease.","Description based on online resource. Title from PDF t.p. (Michigan State University Fedora Repository, viewed ).","Includes bibliographical references."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf","1 online resource (212 p.) : ill."]},{"key":"dc:title","label":"Title","values":["VASCULAR CHEMERIN AS A DRIVER OF OBESITY-RELATED HYPERTENSION AND VASCULAR STIFFNESS"]}]}],"canonical_facts":{"dc:contributor":["Watts, Stephanie W","Alan, Jamie","Fink, Gregory D","Mullick, Adam"],"dc:creator":["Wabel, Emma Ann"],"dc:date":["2026"],"dc:description":["Thesis (Ph.D.)--Michigan State University. Pharmacology and Toxicology - Doctor of Philosophy, 2026","Chemerin is an adipokine steadily gaining attention as a factor in human disease. Circulating levels of chemerin are positively associated with a host of pathologies, including obesity, hypertension, and vascular stiffness. Chemerin causes direct vasoconstriction of isolated blood vessels through the Chemerin1 receptor. Loss of chemerin results in modest falls in blood pressure in standard diet-fed rats and major falls in blood pressure in rats made hypertensive by high fat diet (HFD) feeding. Though the liver makes the majority of chemerin in circulation, loss of chemerin in the liver alone does not significantly change blood pressure. Recognizing that chemerin drives adiposity-associated hypertension, but contributions of chemerin by the liver are not responsible for this, we in turn hypothesize that the chemerin made in the vasculature—the blood vessels and their surrounding perivascular adipose tissue (PVAT)—is important for blood pressure support and pathology. We first investigated chemerin production in and activity at the vasculature. We visualized chemerin (Rarres2) and Chemerin 1 receptor (CMKLR1) expression in each layer of the vasculature— the endothelium, media, adventitia, and PVAT. Then, using the Chemerin1 selective inhibitor CCX832, we demonstrated that chemerin supports basal (uncontracted) blood vessel tone. Next, we sought to identify potential mechanisms that chemerin alters vascular function. We found that inhibition of the receptor Chemerin1 via CCX832 blunted norepinephrine and serotonin-induced vasoconstriction in the male rat, indicating chemerin’s role in amplifying some forms of agonist-induced vasoconstriction. This finding was observed only in vessels with PVAT intact, indicating that it is likely chemerin from the PVAT that drives this effect. Further, chemerin’s amplification of contractile agents occurred only in vessels from male rats, not female rats, indicating a potential sex-dependent role of chemerin in vessel contractility. We then investigated chemerin’s role in adiposity-associated hypertension in whole animals. Administration of CCX832 reduced blood pressure in HFD-induced, but not HSD-induced hypertensive males, supporting that chemerin’s effects on blood pressure are adiposity-related and at least in part Chemerin1-mediated. KO of chemerin blunted HFD-induced hypertension in males and exacerbated it in females, revealing a sex difference previously undiscovered. Interestingly, male KO rats were also protected from HFD-induced aortic stiffening, a blood pressure-independent marker of cardiovascular disease. We consistently observe that chemerin plays a more significant role in HFD-induced diseased vs normal states. What continues to perplex us is how this protein has a greater effect in the body. We investigated whether chemerin processing—cleavage from inactive Chemerin-163 to active Chemerin-157—changed in tissues isolated from CD and HFD animals. However, due to rapid degradation of the chemerin protein, measures could not be achieved. Insight into chemerin’s instability in the body indicates that chemerin is produced, released, and activated locally to exert its effects. Together, these data identify the vasculature as an important site of chemerin synthesis and activity, highlight a previously-missed sex difference for chemerin in vessel contractility and blood pressure, and propose a mechanism by which chemerin’s control in cardiovascular health and diseases hinges. Through this body of work, we assert the adipokine chemerin as a sex-specific therapeutic target in cardiovascular disease.","Description based on online resource. Title from PDF t.p. (Michigan State University Fedora Repository, viewed ).","Includes bibliographical references."],"dc:format":["application/pdf","1 online resource (212 p.) : ill."],"dc:identifier":["etd:53147","local:Wabel_grad.msu_0128D_22164","https://doi.org/doi:10.25335/tvsb-q426"],"dc:language":["eng"],"dc:relation":["Electronic Theses & Dissertations"],"dc:rights":["In Copyright"],"dc:subject":["Pharmacology","Physiology"],"dc:title":["VASCULAR CHEMERIN AS A DRIVER OF OBESITY-RELATED HYPERTENSION AND VASCULAR STIFFNESS"],"dc:type":["text","Electronic dissertations"]},"updated_at":"2026-11-18T18:59:41Z"}